MiR-200a-mediated suppression of non-muscle heavy chain IIb inhibits meningioma cell migration and tumor growth in vivo

Oncogene

Volumn 34, Issue 14, 2014, Pages 1790-1798

  Senol, O ^a   Schaaij Visser, T B M ^b   Erkan, E P ^c   Dorfer, C ^c   Lewandrowski, G ^a   Pham, T V ^b   Piersma, S R ^b   Peerdeman, S M ^b   Strobel T ^d   Tannous, B ^a   Saydam, N ^c   Slavc, I ^c   Knosp, E ^c   Jimenez, C R ^b   Saydam, O ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MIRN200 MICRORNA, HUMAN; MYOSIN HEAVY CHAIN; MYOSIN IIB; NONMUSCLE MYOSIN TYPE IIB HEAVY CHAIN; SMALL INTERFERING RNA;

ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL MOTION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MENINGIOMA; MOUSE; NUDE MOUSE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; MICE; MICE, NUDE; MICRORNAS; MYOSIN HEAVY CHAINS; NEOPLASM TRANSPLANTATION; NONMUSCLE MYOSIN TYPE IIB; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSPLANTATION, HETEROLOGOUS;

EID: 84900969668     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2014.120     Document Type: Article

References (29)

1. Ragel BT, Jensen RL. Aberrant signaling pathways in meningiomas. J Neurooncol 2010; 99: 315-324.
2. Pramesh CS, Saklani AP, Pantvaidya GH, Heroor AA, Naresh KN, Sharma S et al. Benign metastasizing meningioma. Jpn J Clin Oncol 2003; 33: 86-88.
3. Figueroa BE, Quint DJ, McKeever PE, Chandler WF. Extracranial metastatic meningioma. Br J Radiol 1999; 72: 513-516.
4. Ragel B, Jensen RL. New approaches for the treatment of refractory meningiomas. Cancer Control 2003; 10: 148-158.
5. Ragel BT, Couldwell WT, Gillespie DL, Wendland MM, Whang K, Jensen RL. A comparison of the cell lines used in meningioma research. Surgical neurology 2008; 70: 295-307 discussion.
6. Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neurooncol 2010; 99: 379-391.
7. Pham MH, Zada G, Mosich GM, Chen TC, Giannotta SL, Wang K et al. Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms. Neurosurg Focus 2011; 30: E7.
8. Saydam O, Senol O, Schaaij-Visser TB, Pham TV, Piersma SR, Stemmer-Rachamimov AO et al. Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas. J Proteome Res 2010; 9: 485-494.
9. Saydam O, Shen Y, Wurdinger T, Senol O, Boke E, James MF et al. Downregulated microRNA-200a in meningiomas promotes tumor growth by reducing E-cadherin and activating the Wnt/beta-catenin signaling pathway. Mol Cell Biol 2009; 29: 5923-5940.
10. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008; 10: 593-601.
11. Hu X, Macdonald DM, Huettner PC, Feng Z, El Naqa IM, Schwarz JK et al. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol 2009; 114: 457-464.
12. Wu Q, Guo R, Lin M, Zhou B, Wang Y. MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. Gynecol Oncol 2011; 122: 149-154.
13. Xia H, Ng SS, Jiang S, Cheung WK, Sze J, Bian XW et al. miR-200a-mediated downregulation of ZEB2 and CTNNB1 differentially inhibits nasopharyngeal carcinoma cell growth, migration and invasion. Biochem Biophys Res Commun 2010; 391: 535-541.
14. Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR. Non-muscle myosin II takes centre stage in cell adhesion and migration. Nat Rev Mol Cell Biol 2009; 10: 778-790.
15. Beach JR, Hussey GS, Miller TE, Chaudhury A, Patel P, Monslow J et al. Myosin II isoform switching mediates invasiveness after TGF-beta-induced epithelialmesenchymal transition. Proc Natl Acad Sci USA 2011; 108: 17991-17996.
16. Betapudi V, Licate LS, Egelhoff TT. Distinct roles of nonmuscle myosin II isoforms in the regulation of MDA-MB-231 breast cancer cell spreading and migration. Cancer Res 2006; 66: 4725-4733.
17. Jacobs K, Van Gele M, Forsyth R, Brochez L, Vanhoecke B, De Wever O et al. Pcadherin counteracts myosin II-B function: implications in melanoma progression. Mol Cancer 2010; 9: 255.
18. Tullio AN, Accili D, Ferrans VJ, Yu ZX, Takeda K, Grinberg A et al. Nonmuscle myosin II-B is required for normal development of the mouse heart. Proc Natl Acad Sci USA 1997; 94: 12407-12412.
19. Lo CM, Buxton DB, Chua GC, Dembo M, Adelstein RS, Wang YL. Nonmuscle myosin IIb is involved in the guidance of fibroblast migration. Mol Biol Cell 2004; 15: 982-989.
20. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011; 147: 992-1009.
21. Sandquist JC, Swenson KI, Demali KA, Burridge K, Means AR. Rho kinase differentially regulates phosphorylation of nonmuscle myosin II isoforms A and B during cell rounding and migration. J Biol Chem 2006; 281: 35873-35883.
22. Eades G, Yao Y, Yang M, Zhang Y, Chumsri S, Zhou Q. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem 2011; 286: 25992-26002.
23. Elson-Schwab I, Lorentzen A, Marshall CJ. MicroRNA-200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion. PLoS ONE 2010; 5: 10.
24. Sureban SM, May R, Lightfoot SA, Hoskins AB, Lerner M, Brackett DJ et al. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res 2011; 71: 2328-2338.
25. Ahmad A, Aboukameel A, Kong D, Wang Z, Sethi S, Chen W et al. Phosphoglucose isomerase/autocrine motility factor mediates epithelialmesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res 2011; 71: 3400-3409.
26. Wilisch-Neumann A, Kliese N, Pachow D, Schneider T, Warnke JP, Braunsdorf WE et al. The integrin inhibitor cilengitide affects meningioma cell motility and invasion. Clin Cancer Res 2013; 19: 5402-5412.
27. Takeda K, Kishi H, Ma X, Yu ZX, Adelstein RS. Ablation and mutation of nonmuscle myosin heavy chain II-B results in a defect in cardiac myocyte cytokinesis. Circ Res 2003; 93: 330-337.
28. Badr CE, Hewett JW, Breakefield XO, Tannous BA. A highly sensitive assay for monitoring the secretory pathway and ER stress. PLoS ONE 2007; 2: e571.
29. Saydam O, Senol O, Wurdinger T, Mizrak A, Ozdener GB, Stemmer-Rachamimov AO et al. miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Res 2011; 71: 852-861.